Brian Elenbaas

Medicine · Health Sciences

19h-index7.3kcitations41works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(11), RNA modifications and cancer(10), Prostate Cancer Treatment and Research(6), DNA Repair Mechanisms(4), Cancer Cells and Metastasis(4)

Publications41 total

Abstract 1171: M9466 (HRS-1167): A highly potent and selective PARP1 inhibitor with DNA trapping activity, monotherapy antitumor activity and synergistic potential with DDR inhibitors and chemotherapies
Cancer Research·2025
Abstract 5617: Combined inhibition of ATR and ATM with tuvusertib and lartesertib (M4076) impacts the tumor microenvironment
Cancer Research·2024
p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab
Scientific Reports·2023· 7 citedOpen Access
Abstract 6212: Inhibition of ATM-dependent checkpoint control and DNA double-strand break repair enhances the efficacy of ATR inhibitors
Cancer Research·2023
Supplementary Table S2 from Identification of <i>SFRP1</i> as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer
2023Open Access
Supplementary Table S1 from Identification of <i>SFRP1</i> as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer
2023Open Access
Supplementary Table S1 from Identification of <i>SFRP1</i> as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer
2023Open Access
Data from Identification of <i>SFRP1</i> as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer
2023Open Access
Supplementary Table S2 from Identification of <i>SFRP1</i> as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer
2023Open Access
Data from Identification of <i>SFRP1</i> as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer
2023Open Access
ATR inhibition augments the efficacy of lurbinectedin in small cell lung cancer
2022Open Access
Abstract 2153: ATR inhibition augments the efficacy of the lurbinectedin in small cell lung cancer
Cancer Research·2022· 2 cited
ATR Inhibition Augments the Efficacy of Lurbinectedin in Small Cell Lung Cancer
SSRN Electronic Journal·2022· 3 citedOpen Access
Abstract 2062: Comprehensive molecular profiling of DNA damage response (DDR) deficiencies in advanced solid tumors using a real-world genomic database
Cancer Research·2021· 2 cited
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress
Cancer Cell·2021· 173 citedOpen Access
Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy
Experimental and Molecular Therapeutics·2019· 3 cited
Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy
Cancer Research·2019· 19 cited
Abstract 2935: Preclinical efficacy of the p70S6K/AKT dual inhibitor M2698 in combination with trastuzumab in models of gastric cancer
Cancer Research·2018
MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models
Oncotarget·2018· 49 citedOpen Access
Abstract 139: M2698, a novel dual inhibitor of p70S6K and Akt: preclinical efficacy in gastric cancer
Cancer Research·2017· 1 cited
page 1 of 3Next →

Frequent Co-authors

Astrid Zimmermann(8), Arnold J. Levine(7), Frank T. Zenke(7), Margaret S. Joesting(7), Steve Perrin(7), Stephen E. Fawell(7), Jeffrey S. Rubin(7), Omar E. Franco(7), Simon W. Hayward(7), Gerald R. Cunha(7), Paul C. Marker(7), Robert A. Weinberg(5), Heike Dahmen(5), Vincent Maréchal(4), Anish Thomas(4), Christopher W. Schultz(4), Yves Pommier(4), William C. Hahn(3), Jean‐Claude Nicolas(3), Parth Desai(3)